Evidence map›Paper›PMID 41613320›Full record

ArticleFrontiers in medicine2025

Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel.

Ghazi Alotaibi, Aamer Aleem, Ahmed Absi, Ahmed S Alaskar, Feras Alfraih, Ayman Alhejazi, Ahlam Almasari, Musa Fares Alzahrani, Ibraheem Motabi, Riad El Fakih

Abstract read
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ghazi AlotaibiDepartment of Medicine, Division of Hematology/Oncology, King Saud University, Riyadh, Saudi Arabia.
Aamer AleemDepartment of Medicine, Division of Hematology/Oncology, King Saud University, Riyadh, Saudi Arabia.
Ahmed AbsiKing Abdulaziz Medical City, Jeddah, Saudi Arabia.
Ahmed S AlaskarKing Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Feras AlfraihKing Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Ayman AlhejaziKing Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.
Ahlam AlmasariKing Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Musa Fares AlzahraniDepartment of Medicine, King Saud University, Riyadh, Saudi Arabia.
Ibraheem MotabiKing Fahad Medical City, Riyadh, Saudi Arabia.
Riad El FakihKing Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia and represents a significant proportion of leukemias diagnosed in the Western countries but the true incidence and relative frequency of CLL compared with other leukemias in Saudi Arabia are not well defined. Survival outcomes in patients with CLL have improved substantially over time, largely due to the emergence of new, effective, and safer therapeutic options across different stages of the disease. There is a need for clear guidance in the optimal selection of patients for therapy, as well as guidance on therapeutic decision-making to achieve the best outcomes and reduce adverse events seen with the treatment. One of the important purposes of development of local guidelines is to unify the management approach of CLL and to facilitate and optimize early patient referral. This paper represents a focused review and consensus guideline from an expert panel in Saudi Arabia to guide diagnosis and management of CLL nationally. Recommendations are provided based on the available literature evidence and following consensus discussion among the expert panel, covering the diagnosis, staging, and management of CLL in the first line and relapsed/refractory settings.

Indexed as

BCL2 inhibitorBTK inhibitorchronic lymphocytic leukemiaconsensusguidelineSaudi Arabia

Identifiers

PMID41613320
PMCPMC12847048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.